Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial

被引:154
|
作者
Rae, C [1 ]
Digney, AL
McEwan, SR
Bates, TC
机构
[1] Univ Sydney, Sch Mol & Microbial Biosci G08, Discipline Biochem, Sydney, NSW 2006, Australia
[2] Macquarie Univ, Macquarie Ctr Cognit Sci, N Ryde, NSW 2109, Australia
关键词
creatine; oral supplementation; intelligence; memory; brain bioenergetics;
D O I
10.1098/rspb.2003.2492
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Creatine supplementation is in widespread use to enhance sports-fitness performance, and has been trialled successfully in the treatment of neurological, neuromuscular and atherosclerotic disease. Creatine plays a pivotal role in brain energy homeostasis, being a temporal and spatial buffer for cytosolic and mitochondrial pools of the cellular energy currency, adenosine triphosphate and its regulator, adenosine diphosphate. In this work, we tested the hypothesis that oral creatine supplementation (5 g d(-1) for six weeks) would enhance intelligence test scores and working memory performance in 45 young adult, vegetarian subjects in a double-blind, placebo-controlled, cross-over design. Creatine supplementation had a significant positive effect (p < 0.0001) on both working memory (backward digit span) and intelligence (Raven's Advanced Progressive Matrices), both tasks that require speed of processing. These findings underline a dynamic and significant role of brain energy capacity in influencing brain performance.
引用
收藏
页码:2147 / 2150
页数:4
相关论文
共 50 条
  • [21] Creatine monohydrate in myotonic dystrophy -: A double-blind, placebo-controlled clinical study
    Walter, MC
    Reilich, P
    Lochmüller, H
    Kohnen, R
    Schlotter, B
    Hautmann, H
    Dunkl, E
    Pongratz, D
    Müller-Felber, W
    JOURNAL OF NEUROLOGY, 2002, 249 (12) : 1717 - 1722
  • [22] Effects of Acute Citrulline Malate Supplementation on CrossFit® Exercise Performance: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study
    Devrim-Lanpir, Asli
    Ihasz, Ferenc
    Demcsik, Mate
    Horvath, Andras Csaba
    Goczan, Pal
    Czepek, Peter
    Takacs, Johanna
    Kimble, Rachel
    Zare, Reza
    Gunes, Fatma Esra
    Knechtle, Beat
    Weiss, Katja
    Rosemann, Thomas
    Heinrich, Katie M.
    NUTRIENTS, 2024, 16 (19)
  • [23] DOUBLE-BLIND PLACEBO-CONTROLLED CROSS-OVER TRIAL OF CISAPRIDE IN POSTGASTRECTOMY PATIENTS WITH DUODENOGASTRIC REFLUX (DGR)
    VAEZI, M
    SEARS, R
    RICHTER, J
    GASTROENTEROLOGY, 1995, 108 (04) : A249 - A249
  • [24] A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease
    Lopez-Sendon Moreno, Jose Luis
    Garcia Caldentey, Juan
    Trigo Cubillo, Patricia
    Ruiz Romero, Carolina
    Garcia Ribas, Guillermo
    Alonso Arias, M. A. Alonso
    Jesus Garcia de Yebenes, Maria
    Maria Tolon, Rosa
    Galve-Roperh, Ismael
    Sagredo, Onintza
    Valdeolivas, Sara
    Resel, Eva
    Ortega-Gutierrez, Silvia
    Laura Garcia-Bermejo, Maria
    Fernandez Ruiz, Javier
    Guzman, Manuel
    de Yebenes Prous, Justo Garcia
    JOURNAL OF NEUROLOGY, 2016, 263 (07) : 1390 - 1400
  • [25] A randomized double-blind, placebo-controlled, cross-over trial (Vestparoxy) of the treatment of vestibular paroxysmia with oxcarbazepine
    Otmar Bayer
    Tatiana Brémová
    Michael Strupp
    Katharina Hüfner
    Journal of Neurology, 2018, 265 : 291 - 298
  • [26] Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial
    Segev, Aviv
    Evans, Anthony
    Hodsoll, John
    Whiskey, Eromona
    Sheriff, Rebecca S.
    Shergill, Sukhi
    MacCabe, James H.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2019, 34 (02) : 101 - 107
  • [27] Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial
    Mainz, Jochen G.
    Schiller, Isabella
    Ritschel, Christiane
    Mentzel, Hans-Joachim
    Riethmueller, Joachim
    Koitschev, Assen
    Schneider, Gerlind
    Beck, James F.
    Wiedemann, Baerbel
    AURIS NASUS LARYNX, 2011, 38 (02) : 220 - 227
  • [28] DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF PROGABIDE AS ADD-ON THERAPY IN EPILEPTIC PATIENTS
    DEPASQUET, EG
    SCARAMELLI, A
    DECACERES, MP
    LHERITIER, C
    FELDMAN, S
    SANTANA, R
    AGUILAR, J
    MUSCH, B
    MORSELLI, PL
    EPILEPSIA, 1991, 32 (01) : 133 - 139
  • [29] A randomized double-blind, placebo-controlled, cross-over trial (Vestparoxy) of the treatment of vestibular paroxysmia with oxcarbazepine
    Bayer, Otmar
    Bremova, Tatiana
    Strupp, Michael
    Huefner, Katharina
    JOURNAL OF NEUROLOGY, 2018, 265 (02) : 291 - 298
  • [30] Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial
    Maxwell J. Roeske
    Maureen McHugo
    Baxter Rogers
    Kristan Armstrong
    Suzanne Avery
    Manus Donahue
    Stephan Heckers
    Neuropsychopharmacology, 2024, 49 : 681 - 689